PEACE-AD is not open to enrollment outside of participating memory and long-term care communities.
About the PEACE-AD Study
The goal of the PEACE-AD clinical trial is to identify a well-tolerated treatment for people with severe agitation in the later stages of Alzheimer’s disease (AD).
PEACE-AD is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial of the drug prazosin in Alzheimer’s disease. There are eight academic medical centers working with approximately 20 long-term memory care communities in the clinical trial. PEACE-AD will enroll 186 participants residing in memory and long term care communities participating in the PEACE-AD trial.
Finding effective treatments for disruptive agitation would address a significant, unmet, public health need.